Ma Liang, Zhao Hailing, Yu Meijie, Wen Yumin, Zhao Tingting, Yan Meihua, Liu Qian, Jiang Yongwei, Cao Yongtong, Li Ping, Niu Wenquan
Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China.
Beijing Key Laboratory of Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China.
Int J Hypertens. 2020 Feb 28;2020:2351547. doi: 10.1155/2020/2351547. eCollection 2020.
BACKGROUND: Epoxide hydrolase 2 () gene coding for soluble epoxide hydrolase is a potential candidate in the pathogenesis of hypertension. OBJECTIVES: We aimed to assess the association of a missense mutation, R287Q, in ) gene coding for soluble epoxide hydrolase is a potential candidate in the pathogenesis of hypertension. METHODS: This study involved 782 patients with primary hypertension and 458 healthy controls. Genotyping was done using TaqMan technique. Activity of soluble epoxide hydrolase fusion proteins was evaluated by the conversion of 11,12-EET to corresponding 11,12-DHET using ELISA kit. RESULTS: After taking carriers of R287Q variant GG genotype as a reference, those with GA genotype had a significantly reduced risk of hypertension (adjusted odds ratio: 0.72, 95% confidence interval: 0.56 to 0.93, = 0.013). Five significant risk factors were identified, including age, body mass index, total cholesterol, homocysteine, and R287Q variant. These five risk factors for hypertension were represented in a nomogram, with a descent prediction accuracy (C-index: 0.833, = 0.013). Five significant risk factors were identified, including age, body mass index, total cholesterol, homocysteine, and R287Q variant. These five risk factors for hypertension were represented in a nomogram, with a descent prediction accuracy (C-index: 0.833. CONCLUSIONS: We provide evidence that R287Q mutation in gene was associated with reduced risk of primary hypertension and low activity of soluble epoxide hydrolase.) gene coding for soluble epoxide hydrolase is a potential candidate in the pathogenesis of hypertension.
背景：编码可溶性环氧化物水解酶的环氧化物水解酶2（）基因是高血压发病机制中的一个潜在候选基因。 目的：我们旨在评估编码可溶性环氧化物水解酶的）基因中的一个错义突变R287Q与高血压发病机制的关联。 方法：本研究纳入了782例原发性高血压患者和458例健康对照。采用TaqMan技术进行基因分型。使用ELISA试剂盒通过将11,12-EET转化为相应的11,12-DHET来评估可溶性环氧化物水解酶融合蛋白的活性。 结果：以R287Q变异体GG基因型携带者为参照，GA基因型携带者患高血压的风险显著降低（校正比值比：0.72，95%置信区间：0.56至0.93，=0.013）。确定了五个显著的风险因素，包括年龄、体重指数、总胆固醇、同型半胱氨酸和R287Q变异体。这五个高血压风险因素在列线图中呈现，预测准确性良好（C指数：0.833，=0.013）。确定了五个显著的风险因素，包括年龄、体重指数、总胆固醇、同型半胱氨酸和R287Q变异体。这五个高血压风险因素在列线图中呈现，预测准确性良好（C指数：0.833）。 结论：我们提供的证据表明，基因中的R287Q突变与原发性高血压风险降低及可溶性环氧化物水解酶活性降低有关。编码可溶性环氧化物水解酶的）基因是高血压发病机制中的一个潜在候选基因。
Int J Hypertens. 2020-2-28
Prostaglandins Other Lipid Mediat. 2014-10
Prostaglandins Other Lipid Mediat. 2018-9
Am J Physiol Renal Physiol. 2011-3-23
J Atr Fibrillation. 2018-12-31
J Am Soc Hypertens. 2016-10
Curr Hypertens Rep. 2014-8
Zotero 插件